Zogenix Inc (ZGNX) Peer Comparison

$26.68

$0.00 (0.00%)

As on 07-Mar-2022 09:30EDT

Market cap

$1,500 Mln

Revenue (TTM)

$82 Mln

P/E Ratio

--

P/B Ratio

8.3

Div. Yield

0 %

Edit

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Market cap ($ Mln)	1,500	2,920	2,195	2,205	1,106
Revenue ($ Mln)	82	450	549	65	4
Net Profit ($ Mln)	-227.41	-188.21	17.88	-94.37	-340.16
Net Margin (%)	-242.56	-41.86	3.26	-144.33	-540.52
RoE (%)	-82.90	-28.46	1.43	-16.10	501.41
Price to Earnings	--	--	126.30	--	--
Price-To-Book	8.26	4.82	1.73	3.93	2.10

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Operating Revenue	81.69	144.31	356.13	7.46	4.19
Cost of Revenue	4.83	52.24	28.79	85.73	1.02
Gross Profit	76.86	92.07	327.34	-78.28	4.19
Operating Expenses	299.07	792.14	684.45	115.06	56.31
Operating Profit (EBIT)	-224.10	-700.06	-357.10	-109.10	-52.11
Other Income	12.07	--	--	--	--
Profit before Tax	-227.31	-703.41	-155.12	-99.63	-49.27
Provision for Tax	0.11	1.06	11.92	-0.82	0.36
Profit after Tax (Net Income)	-227.41	-704.47	-194.65	-98.81	-49.64
Minority Interest	--	--	--	--	--
Consolidated Profit	-227.41	-704.47	-194.65	-98.81	-49.64

Liabilities ($ Mln)

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Shareholder's Funds	178.97	1,379.96	986.89	581.40	88.87
Minority Interest	--	--	--	--	--
Non-Current Liabilities	191.82	37.10	21.49	69.05	10.27
Current Liabilities	97.69	192.90	311.66	94.27	22.85
Total Liabilities	468.49	1,609.96	1,372.66	744.72	121.99

Assets ($ Mln)

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Non-Current Assets	113.92	109.08	160.59	596.49	6.41
Current Assets	354.57	1,500.88	1,212.08	148.23	115.58
Total Assets	468.49	1,609.96	1,372.66	744.72	121.99
Total Debt*	168.48	15.54	38.98	105.50	10.12
Net Current Assets	256.87	1,307.98	900.42	53.95	92.73

Cashflow ($ Mln)

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Cash From Operating Activities	-185.31	-549.23	-204.22	-106.68	-47.63
Cash Flow from Investing Activities	137.40	249.96	-306.32	-1.65	-1.79
Cash from Financing Activities	-17.83	820.20	650.03	114.47	25.45
Net Cash Inflow / Outflow	-65.74	--	--	--	--

Ratios

Profitability Ratios

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
ROCE (%)	-52.39	-54.54	-25.13	-14.80	-45.07
ROE (%)	-82.90	-55.27	-26.46	-17.48	-49.62
ROA (%)	-40.62	-48.46	-18.57	-13.37	-38.05
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	-242.56	-488.16	-54.66	-1,325.25	-1,183.50
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Revenue Growth (%)	4.99	1.95	0.56	-0.77	10.27
EBIT Growth (%)	--	--	--	--	--
Net Profit Growth (%)	-8.61	-161.98	-54.81	-26.78	-56.96
EPS Growth (%)	-0.05	-1.40	-0.31	-0.07	-0.52
Book Value Growth (%)	--	--	--	--	--

Valuation Ratios

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Price / Earnings	-4.00	-85.15	-30.86	-4.90	-10.90
Price / Book Value	5.08	43.47	6.09	0.83	6.09
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.83	-84.98	-32.58	-5.35	-8.64
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Debt to Equity	0.94	0.01	0.04	0.18	0.11
Short term debt to equity ratio	0.01	0.00	0.03	0.10	0.01
Current Ratio	3.63	7.78	3.89	1.57	5.06
Quick Ratio	3.57	7.68	3.77	1.57	5.04
Interest Coverage	--	-207.75	-363.43	-8.30	-388.55

Operating Efficiency Ratios

	Zogenix Inc (ZGNX)	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Inventiva Sa (IVA)
Debtors to sales (%)	12.41	37.98	41.48	61.56	276.28
Asset Turnover	0.15	0.10	0.34	0.01	0.03
Receivable days	31.22	75.90	100.31	144.81	506.64
Inventory Days	246.25	112.20	352.24	-1.07	127.86
Payable days	1,282.34	660.05	461.79	94.94	3,865.30
Cash Conversion Cycle	-1,004.88	-471.95	-9.25	48.79	-3,230.80

Annual
Quarterly